| Literature DB >> 26383093 |
Kirsty Challen1, Mike Bradburn2, Steve W Goodacre3.
Abstract
BACKGROUND: Risk stratification methods developed on the basis of predicting illness severity are often used to prioritise patients on the basis of urgency. Illness severity and urgency may not be interchangeable. Severe illness places patients at risk of adverse outcome, but treatment is only urgent if adverse outcome can be prevented by time-sensitive treatment. We aimed to develop a score to identify patients in need of urgent treatment, on the basis of potential to benefit from time-sensitive intervention, and to compare this with a severity score identifying patients at high risk of death.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26383093 PMCID: PMC4574211 DOI: 10.1186/s13049-015-0150-y
Source DB: PubMed Journal: Scand J Trauma Resusc Emerg Med ISSN: 1757-7241 Impact factor: 2.953
Interventions defined a priori as potentially life-saving
| Airway interventions |
| • Use of airway adjunct or procedure to maintain patent airway. |
| • Use of intravenous/intramuscular adrenaline to treat or prevent airway compromise. |
| Breathing interventions |
| • Bag-valve-mask ventilation (unless during procedural sedation), intermittent positive pressure ventilation, or non-invasive ventilation. |
| • Decompression of tension pneumothorax. |
| • Drainage of significant pleural effusion (>1 litre). |
| • Insertion of chest drain for pneumothorax in patients with pre-existing lung disease. |
| • Intravenous therapy except steroids for asthma. |
| Circulation interventions |
| • Cardioversion (chemical or DC) of ventricular tachycardia or supraventricular tachycardia or atrial fibrillation with accessory pathway. |
| • CPR. |
| • Emergency endoscopy or surgery for upper GI bleed or use of Sengstaken tube or use of vasopressin/terlipressin. |
| • Infusion of >2 litres of fluid or transfusion for haemodynamic instability. |
| • Laparotomy for GI bleed/gynaecological bleed (including ectopic)/AAA. |
| • Sepsis care bundle. |
| • Thrombolysis for AMI or PE, or percutaneous revascularisation. |
| • Therapeutic (not diagnostic) pericardiocentesis. |
| • Transcutaneous or external pacing or administration of atropine (except in theatre). |
| • Vasopressor use (except bolus dosing in theatre). |
| Disability interventions |
| • Administration of naloxone or flumazenil (unless related to procedural sedation). |
| • Administration of 10 %/50 % dextrose. |
| • Administration of >1 dose benzodiazepines/other anticonvulsants for fitting. |
| • Neurosurgical intervention. |
| Other interventions |
| • Active rewarming (not including Bearhugger). |
| • Laparotomy for sepsis/infarction/obstruction. |
| • New initiation of renal replacement therapy. |
| • Specific poisons antidotes including N-acetylcysteine. |
Fig. 1Consort diagram
Patient demographics
| Derivation cohort | Validation cohort | |||
|---|---|---|---|---|
| Full cohort for death ( | Subset for potential to benefit ( | Full cohort for death ( | Subset for potential to benefit ( | |
| Variable | Mean (sd; range) | |||
| Age | 69 (19; 18–103) | 66.5 (20.2; 18–102) | 70 (19; 18–103) | 71.3 (18.3; 19–96) |
| Respiratory rate | 19 (6;6–60) | 20 (7; 6–45) | 20 (6.6; 8–80) | 20 (5.8; 12–40) |
| Systolic BP | 136 (29; 24–266) | 133 (29; 45–243) | 139 (28.4; 44–261) | 138 (28.6; 60–249) |
| Diastolic BP | 75 (15; 30–153) | 75 (15; 36–130) | 76 (15; 11–151) | 74 (15; 36–142) |
| Pulse rate | 88 (24; 21–215) | 92 (24; 35–188) | 88 (23; 20–180) | 89 (21.9; 35–152) |
| Temperature | 36.6 (1.2; 26.0–41.0) | 36.5 (1.2; 26.0–40.0) | 36.5 (1.1; 25.2–40.5) | 36.6 (1.40; 26.4–39.6) |
| Variable | Median (IQR; range) | |||
| SaO2 breathing air | 97 (95–98; 50–100) | 97 (94–98; 66–100) | 97 (95–98; 45–100) | 96 (94–98; 45–100) |
| SaO2 breathing oxygen | 98 (95–100; 24–100) | 97 (96–99; 71–100) | 98 (95–100; 60–100) | 98 (96–100; 84–100) |
| GCS | 15 (15–15; 3–15) | 15 (15–15; 3–15) | 15 (15–15; 3–15) | 15 (15–15; 7–15) |
| Variable | Number (percentage) | |||
| Male | 1131 (46.4) | 183 (46) | 1093 (46.5) | 95 (42) |
| Active malignancy | 110 (4.5) | 23 (5.8) | 96 (4.1) | 6 (2.7) |
| Outcomes | Number (percentage) | |||
| All deaths | 128 (5.2) | 141 (6.0) | ||
| Inevitable death | 15 (3.7) | 2 (0.8) | ||
| Potentially preventable death | 5 (1.2) | 1 (0.4) | ||
| Prevented death | 79 (19.8) | 35 (15.4) | ||
Univariate logistic regression analysis of predictor variables for potential to benefit
| Variable | exp(B) |
| 95 % CI for exp(B) | |
|---|---|---|---|---|
| Pulse (ref <71) | <0.001 | |||
| 71–110 | 0.522 | 0.316 | 0.862 | |
| >110 | 3.756 | 1.930 | 7.309 | |
| Respiratory rate (ref <16) | <0.001 | |||
| 16–18 | 1.009 | 0.605 | 1.683 | |
| 19–23 | 3.463 | 1.819 | 6.594 | |
| >23 | 3.991 | 2.140 | 7.443 | |
| Systolic BP (ref 121–180) | <0.001 | |||
| <100 | 4.461 | 2.397 | 8.302 | |
| 100–120 | 2.140 | 1.250 | 3.665 | |
| >180 | 31.475 | 13.479 | 73.496 | |
| Pulse pressure (ref 51–76) | <0.001 | |||
| <51 | 1.791 | 1.143 | 2.805 | |
| >76 | 3.540 | 2.030 | 6.174 | |
| GCS (ref 13–15) | <0.001 | |||
| 3–8 | 34.446 | 16.607 | 71.447 | |
| 9–12 | 2.203 | 1.235 | 3.930 | |
| SaO2 (ref low risk (99–100 breathing air)) | <0.001 | |||
| High (<95 breathing air or <96 with supplemental O2) | 1.583 | 0.156 | 0.839 | 2.987 |
| Moderate (95–98 breathing air or >95 with supplemental O2) | 0.470 | 0.004 | 0.283 | 0.781 |
Multivariate analysis of predictor variables for potential to benefit
| Variable | exp(B) |
| 95 % CI for exp(B) | |
|---|---|---|---|---|
| Pulse (ref <71) | 0.02 | |||
| 71–110 | 0.371 | 0.034 | 4.101 | |
| >110 | 5.176 | 1.125 | 23.816 | |
| Respiratory rate (ref <16) | 0.228 | |||
| 16–18 | 4.814 | 0.636 | 36.443 | |
| 19–23 | 19.144 | 1.035 | 354.172 | |
| >23 | 6.664 | 0.723 | 61.405 | |
| Systolic BP (ref 121–180) | 0.061 | |||
| <100 | 3.687 | 1.089 | 12.481 | |
| 100–120 | 1.112 | 0.407 | 3.043 | |
| >180 | 2.468 | 0.615 | 9.905 | |
| Pulse pressure (ref 51–76) | 0.536 | |||
| <51 | 1.479 | 0.548 | 3.992 | |
| >76 | 1.729 | 0.611 | 4.894 | |
| GCS (ref 13–15) | <0.001 | |||
| 3–8 | 23.013 | 3.806 | 139.163 | |
| 9–12 | 4.060 | 1.114 | 14.790 | |
| SaO2 (ref low risk) | 0.971 | |||
| High | 0.946 | 0.146 | 6.123 | |
| Moderate | 0.840 | 0.164 | 4.300 | |
| Pulse/SaO2 interaction | 0.210 | |||
| Respiratory rate/SaO2 interaction | 0.210 | |||